Back to top
more

Radius Recycling, Inc. (RDUS)

(Delayed Data from NSDQ)

$17.86 USD

17.86
175,728

+0.31 (1.77%)

Updated May 3, 2024 04:00 PM ET

After-Market: $17.86 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 252)

Industry: Waste Removal Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.

Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed a recovery in rapid immunoassay revenues during Q4.

InMode (INMD) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have contributed to the company's Q4 top line.

Canopy Growth (CGC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal third quarter.

Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis

by Zacks Equity Research

Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.

Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution

by Zacks Equity Research

Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.

Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs

by Zacks Equity Research

Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.

Radius Health (RDUS) Up 3.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radius' (RDUS) Q3 Loss Matches Estimates, Revenues Miss

by Zacks Equity Research

Radius (RDUS) reports an in-line loss but misses sales estimates in the third quarter.

Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of 0.00% and -5.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Radius Health (RDUS) Down 7% Since Last Earnings Report?

by Zacks Equity Research

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radius Completes Enrollment in Phase III Osteoporosis Study

by Zacks Equity Research

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.

Radius Health (RDUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Radius Health (RDUS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Radius Health (RDUS) Down 11.6% Since Last Earnings Report?

by Zacks Equity Research

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.

Radius Health (RDUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Radius Health (RDUS) Down 33.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength

by Zacks Equity Research

Radius (RDUS) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2019 as Tymlos gains traction.

Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of 27.03% and 4.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel.

Is a Surprise Coming for Radius Health (RDUS) This Earnings Season?

by Zacks Equity Research

Radius Health (RDUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Moving Average Crossover Alert: Radius Health

by Zacks Equity Research

Radius Health, Inc. (RDUS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.